EMA starts rolling review of CureVac’s covid-19 vaccine

EMA’s human medicines committee (CHMP) has started a rolling review of covid-19 vaccine by CureVac AG. The CHMP’s decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults. It may get approval by summer.